Implementable Strategies and Exploratory Considerations to Reduce Costs Associated with Anti-TNF Therapy in Inflammatory Bowel Disease: by Park, K. T. et al.
Implementable Strategies and Exploratory Considerations to
Reduce Costs Associated with Anti-TNF Therapy in
Inflammatory Bowel Disease
KT Park1, Wallace V. Crandall2, Jacqueline Fridge3, Ian H. Leibowitz4, Marc Tsou5, Dana
Dykes6, Edward J. Hoffenberg7, Michael D. Kappelman8, and Richard B. Colletti9
1Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Center for
Health Policy/Primary Care Outcomes Research, Stanford University School of Medicine, Palo
Alto, CA
2Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, The Ohio
State University College of Medicine, Columbus, OH
3Northwest Pediatric Gastroenterology LLC, Randall Children’s Hospital, Portland, OR
4Children’s Digestive Disease Program, Inova Fairfax Hospital for Children, Fairfax, VA
5Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Eastern
Virginia Medical School, Norfolk, VA
6Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of
Cincinnati College of Medicine, Cincinnati, OH
7Section of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of
Colorado Denver School of Medicine, Denver, CO
8Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics,
University of North Carolina School of Medicine, Chapel Hill, NC
9Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of
Vermont College of Medicine, Burlington, VT
Abstract
A health care system is needed where care is based on the best available evidence and is delivered
reliably, efficiently, and less expensively (best care at lower cost). In gastroenterology, anti-tumor
necrosis factor (anti-TNF) agents represent the most effective medical therapeutic option for
patients with moderate-to-severe inflammatory bowel disease (IBD), but are very expensive and
account for nearly a quarter of the cost of IBD care, representing a major area of present and
future impact in direct health care costs. The ImproveCareNow Network, consisting of over 55
pediatric IBD centers, seeks ways to improve the value of care in IBD – curtailing unnecessary
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costs and promoting better health outcomes through systematic and incremental quality
improvement initiatives. This report summarizes the key evidence to facilitate the cost-effective
use of anti-TNF agents for patients with IBD. Our review outlines the scientific rationale for
initiating cost-reducing measures in anti-TNF use and focuses on three implementable strategies
and four exploratory considerations through practical clinical guidelines, as supported by existing
evidence. Implementable strategies can be readily integrated into today’s daily practice, while
exploratory considerations can guide research to support future implementation.
INTRODUCTION
In its 2013 report, “Best Care at Lower Cost”, the Institute of Medicine advocates for a
health care system where care is based on the best available evidence and is delivered
reliably, efficiently, and less expensively1. The Institute of Medicine has estimated that there
are excess costs of $130 billion annually due to inefficiently delivered services, and an
additional $210 billion due to unnecessary services. It also concludes that systematic,
evidence-based process improvement methods applied in various industrial sectors to
achieve often striking results in safety, quality, reliability, and value can be similarly
transformative for health care, improving outcomes and lowering cost.
It has been estimated that claims paid for Crohn’s disease average $24,175 per patient per
year, and that 24% of those costs are for treatment with anti-tumor necrosis factor (anti-
TNF) drugs, an amount approximating the cost of inpatient hospitalizations2. The
anticipated 3-year compounded increase in annual spending in the United States for anti-
TNF use in inflammatory conditions is 72.2%3.
Anti-TNF agents, such as infliximab (Remicade™) 4,5,6,7,8, adalimumab
(Humira™)9,10,11,12,13,14 and certolizumab pegol (Cimzia™)15,16, represent the most
effective medical therapeutic option for patients with moderate-to-severe inflammatory
bowel disease (IBD), either Crohn’s disease (CD) or ulcerative colitis (UC). Recent trends in
induction and maintenance therapies for CD and UC have focused on increasing anti-TNF
use, with new biological agents receiving attention in published safety and efficacy multi-
center clinical trials17,18,19,20,21,22,23,24,25 or approval for treatment of IBD26.
In light of increasing anti-TNF use, these drugs represent the primary focal point where
gastroenterologists can lead the effort to control health care costs in IBD without
compromising the quality of care or outcomes. Judicious and evidence-based use of anti-
TNFs will continue to be a vital policy effort for the present and foreseeable future of IBD
care. A recent editorial succinctly communicates the overarching message of this clinical
review: value-conscious gastroenterologists can work together to optimize IBD care plans
involving anti-TNFs27.
Given these considerations, physician members of the ImproveCareNow Network formed
the Reducing Cost Strategic Initiative for Biologic Therapies, and initially outlined all
potential areas for cost-reduction. ImproveCareNow is a primarily US-based, growing multi-
center pediatric IBD collaborative formed in 2007, currently consisting of over 55 pediatric
care centers and representing more than 15,000 children and youth with CD and UC28,29,30.
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The aim of this review is to outline the best available evidence to initiate cost-reduction
strategies within the standard-of-care models for anti-TNF use. Formative clinical reviews
and editorials have already summarized the increasing evidence from original studies and
described the scientific rationale for various clinical strategies associated with anti-TNF
use31,32,33,34,35. However, no report exists to date to contextualize the practical clinical
application of anti-TNF use within an organized effort to streamline direct health care costs
and reduce over-utilization.
Within the framework of the published literature and our collective patient-care experience,
the goal of this report is to answer the primary question: What are implementable strategies
and exploratory considerations for cost-efficient anti-TNF use while maintaining the highest
quality of IBD care? What is best care at lower cost? Implementable strategies represent
recommendations with significant evidence to support cost-effective clinical practice.
Exploratory considerations represent possible interventions based on emerging evidence for
other cost-effective clinical practices.
IMPLEMENTABLE STRATEGIES
Implementable Strategy #1: Reduce costs of avoidable dose intensification or class
switching by eliminating episodic anti-TNF use and improving patient education
Evidence suggests that long-term durability of anti-TNF effectiveness is associated with
improved health outcomes36,37. Administering regularly scheduled anti-TNF infusions and
eliminating episodic anti-TNF use are necessary to optimize its effectiveness. Meticulously
scheduled anti-TNF maintenance therapy will curb over-utilization associated with
unnecessary or preventable dose escalation or class switching. Such practice will improve
patient outcomes38,39, increase cost-effectiveness40, enhance drug efficacy41, reduce
premature immunogenicity through auto-antibody formation, and decrease the probability of
early drug tolerance42,.
Studies show that failure to adhere to agreed-upon regimens contributes to worse health
outcomes. Direct costs of IBD care from loss of response (LOR) to anti-TNF therapy may
be more attributable to non-adherence than drug efficacy43. When the patient and
gastroenterologist decide to implement anti-TNF therapy for the induction and remission of
IBD, it is important to agree upon the therapeutic goal of sustainability, not rescue – to
enhance the probabilities of long-term response of the initial anti-TNF therapy. It is not
uncommon for patients and families to wish to prematurely withdraw from a successful anti-
TNF regimen, especially among patients who have attained remission and good quality-of-
life on biologics but are averse to the idea of prolonged or escalated drug therapy. Patients
would benefit from an early introduction to and adoption of the evidence-based rationale
against episodic anti-TNF therapy. Agreeing upon maintaining a long-term scheduled anti-
TNF regimen after achieving clinical remission, or for at least 1 year after achieving
complete mucosal healing, will improve outcomes, especially patients who are on self-
injectable anti-TNF agents44,45.
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Implementable Strategy #2: Reduce over-utilization costs by accurately determining
indication for escalating anti-TNF use
Evidence from a recent meta-analysis reports a 25% to 46% probability of concomitant
irritable bowel syndrome (IBS) in IBD patients.46 However, clinical signs and symptoms in
patients with IBS and IBD are especially difficult to attribute to one or both diseases. For
gastroenterologists, avoiding the use of anti-TNFs to treat patients with symptoms due to
IBS is particularly important in reducing over-utilization and minimizing harm. A
prospective, cross-sectional cohort study reports that the Crohn’s disease activity index
could not distinguish between IBS and CD patients47. Empiric dose escalation, increase in
frequency, or class switching in patients with IBS and IBD without objectively determining
systemic and/or mucosal inflammation will frequently lead to over-utilization. To avoid
misuse or overuse, recommendations include: ruling out infectious causes (e.g., C. difficile
infection), checking for serological markers for inflammation (i.e., C-reactive protein and
complete blood count parameters), and measuring fecal calprotectin prior to initiating or
adjusting anti-TNF regimens. Additionally, on a case-by-case basis, low- or non-ionizing
radiologic studies (e.g., ultrasound and magnetic resonance enterography) and endoscopic
index scoring (e.g., Crohn’s disease endoscopic index score) can be utilized to clarify the
clinical picture between IBS and IBD48,49.
In specifically detecting sub-clinical inflammation in IBD patients with IBS-type symptoms,
there is evidence for measurements of calprotectin as a biomarker for mucosal
inflammation50. Determination of fecal calprotectin to assess mucosal status may not be
cost-prohibitive, as Medicare reimbursement is $28 per assay in 2012,51 although costs to
private insurers may be higher. There are two systematic reviews and meta-analyses that
highlight the potential for non-invasively detecting acute and chronic mucosal inflammation
using calprotectin. The first meta-analysis pooled data from 13 studies, including 6 in adults
and 7 in children and adolescents, and report a pooled sensitivity and specificity of 0.93 and
0.96 in adults and 0.92 and 0.76 in children52. The second meta-analysis reviewed 8 studies
in pediatric cohorts and reported a pooled sensitivity and specificity of 0.978 and 0.682 for
pediatric IBD53. A recent cost-effectiveness analysis shows that any value greater than 50
μg/g maximizes the sensitivity of calprotectin for mucosal inflammation and supports the
utility of fecal calprotectin as a biomarker test when clinical suspicion alone for mucosal
inflammation is ambiguous54. This is directly applicable in determining whether patients on
anti-TNF therapies may need dose intensification. Future work is needed to determine
whether there is any histopathologic difference or likelihood of mucosal healing based on
specific calprotectin positivity thresholds (i.e., 50,100, or 200 μg/g).
Implementable Strategy #3: Reduce non-drug infliximab costs through shortened infusion
times after initial safety is clearly established
Evidence suggests that non-drug costs associated with infliximab infusions are substantial.
In the U.S., non-drug costs of infliximab administration for IBD may be greater than the
actual drug costs in medical practices using hospital- or infusion center-based sites. One
analysis reports that personnel costs required to administer the drug based 771 encounters
for infliximab at a pediatric tertiary care center is 77% of the total health care cost for each
infusion encounter55. Transparency of cost is difficult, and heterogeneity of charges to
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reimbursements is likely; nonetheless, reducing non-drug costs is an opportunity to
substantially reduce the cost of anti-TNF treatment.
Patient safety must precede considerations for cost-efficiency or convenience. Given this
priority of “first-do-no-harm,” the available evidence suggests that non-drug costs associated
with infliximab administration can be safely reduced by abbreviating the typical 2- to 3-hour
infusion period to ≤ 1-hour. A recent meta-analysis which included pediatric data when
available concluded no increase in adverse reactions associated with the abbreviated
infusion of infliximab56. In particular, when prior infusions have shown no adverse reactions
on the standard 2- to 3-hour infusion period, patients undergoing shortened infusion times of
infliximab under a carefully monitored medical care setting can reduce both future
opportunity loss (e.g., time away from work or school) for the patient and/or family and
direct healthcare costs. The current data for this strategy are more robust in adults than in
children. Among the 13 original studies in the meta-analysis, 2 studies included adult and
pediatric patients as young as 14 years of age while 1 pediatric study considered patients as
young as 12 years of age. Currently, certain ImproveCareNow Network centers have been
using 1-hour maintenance infliximab infusion protocols in acute care settings after patients
safely undergo 3 initial infliximab doses at 2- to 3- hour infusions. Of note, infusions in a
monitored acute care settings is still the current standard of care, although preliminary
results for home infusions appear to be cost-efficient with high patient satisfaction57.
However, at this time, there is insufficient evidence to support the safety of large scale home
infusion programs, particularly in children.
EXPLORATORY CONSIDERATIONS
Exploratory Consideration #1: Self-injectable anti-TNFs
Since prospective comparative effectiveness research is limited between anti-TNF
therapies58, a formal head-to-head evaluation between infliximab and adalimumab for CD or
UC when initiating anti-TNF therapy is not available – although retrospective analysis
between the two drugs finds similar effectiveness in CD after 26 weeks of treatment59. In
pediatrics, infliximab is the only anti-TNF that is FDA-approved in children, but off-label
use of adalimumab is not uncommon. Clinicians and patients should make it a priority to
discuss disease management expectations and logistical differences when starting on either
infliximab or adalimumab, seeking to individually tailor the regimen to a patient’s lifestyle
and realistic estimation for long-term medication adherence. In our experience, self-
injectable agents may have added risk of non-adherence leading to worse outcomes among
adolescent IBD patients. The tradeoff between cost-savings and potential for worse
outcomes due to non-adherence with self-injectable anti-TNFs is unknown. More clarity is
needed regarding the difference in total direct costs between anti-TNF infusions and self-
injectables.
Exploratory Consideration #2: Combination therapy
Immunomodulators, in the form of 6-mercaptopurine and its pro-drug azathioprine, are very
cost-affordable drugs compared to anti-TNFs. Based on an azathioprine therapeutic dose of
100 mg per day, the annual drug cost would be less than $150060. Although a formal cost-
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effectiveness analysis is not yet available, the use of adjunct immunomodulators in
combination with anti-TNF agents (i.e., combination therapy) are shown in randomized
clinical trials to be more effective than anti-TNF monotherapy in efficiency and
sustainability of clinical response. In CD, the SONIC trial for moderate-to-severe CD
patients achieved significant incremental benefit with combination therapy over
monotherapy (56.8% vs. 44.4% steroid-free remission) at week 26 for patients previously
naïve to both agents61. Preliminary results show combination therapy to be superior to
infliximab monotherapy in long-term outcomes in perianal fistulizing CD62. In UC,
preliminary data from the SUCCESS trial duplicate the trends reported in CD. Combination
therapy was superior to montherapy (40% vs. 22% steroid free remission) at week 1663.
Although more longitudinal data are needed to understand long-term costs and benefits,
extrapolation of direct costs of IBD health states in good versus poor control would validate
combination therapy as a cost-saving measure. Also, a more precise estimate of additional
risk of rare but serious events (e.g., lymphoma) is important for patients on combination
therapy.
Exploratory Consideration #3: Monitoring of anti-TNF drug levels and auto-antibodies
Gastroenterologists now have the option to monitor infliximab and adalimumab drug levels
and auto-antibodies through commercial assays with a high-degree of accuracy and
precision64,65. Cost-effective clinical care using an individualized anti-TNF dosing strategy
depends on the usefulness of these tests, clinician interpretation of the results, and the
baseline cost of the laboratory assays. To determine the etiology for LOR, a clinician is
faced with interpreting whether one or a combination of drug levels and auto-antibodies
suggests anti-drug antibody, immune complex formations66,67 or patient-specific accelerated
drug clearance68 to determine the etiology for LOR. One randomized, controlled, single-
blind multi-center study of 69 patients showed that individualized infliximab therapy based
on drug levels and auto-antibody titers results in similar clinical response rates and lower
treatment costs compared to the dose intensification strategy69. A formal cost-effectiveness
analysis in CD patients corroborates this trial. Although remission rates were similar over a
1 year period, a testing-based strategy cost $6,000 less than the empiric dose escalation
strategy among patients with secondary LOR70. A weakness in this analysis includes
missing the true cost of drug level testing, because out-of-pocket costs to the patients were
not considered along with a higher cost of drug level testing71. At present, less cost-
prohibitive drug level and auto-antibody testing for anti-TNF agents are entering the market,
which may provide gastroenterologists more options in the near future. In the meantime,
gastroenterologists should carefully weigh individual benefits and costs to patients and
families.
Exploratory Consideration #4: Complete mucosal healing as a clinical endpoint
The evolving thought is that complete mucosal healing should be considered the major
therapeutic goal in IBD, especially in UC72,73,74. Complete mucosal healing refers to the
absence of mucosal breakdown and ulcerations on endoscopic assessment75. The working
hypothesis is that disease management with early and aggressive anti-TNF use can modify
the future disease course by maintaining complete mucosal healing, as described in the
literature by the phrase “deep remission”76,77,78. Complete mucosal healing is now
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considered a primary clinical endpoint in newer randomized trials – such as in the EXTEND
(Extend the safety and efficacy of adalimumab through endoscopic healing) study79. In this
trial using adalimumab, complete mucosal healing was evaluated by ileocolonoscopy, and
investigators found that 15/62 patients achieved this endpoint at weeks 12 and 52. Although
the application of complete mucosal healing in clinical practice is not yet known, the
implications on cost-effective use of anti-TNF agents are important to discuss. For example,
if achievement of present-day complete mucosal healing renders a relapsing and remitting
IBD form to be more manageable and less aggressive in the future, this consideration has the
potential for major cost-benefit impact. While additional costs may be required up front for
more aggressive use of anti-TNF agents and more frequent endoscopic evaluations,
especially soon after diagnosis, the overall cost-savings may result later from averted future
healthcare use. At this time, considering this lifetime perspective is difficult because more
data about the significance of complete mucosal healing are required to make formal
recommendations.
CONCLUSION
Gastroenterologists have an opportunity to play a leading role in providing the best care at
lower cost for patients with IBD by administering anti-TNFs with an evidence-based
approach that is more efficient and eliminates unnecessary services. In today’s era of
biologics for the management of IBD, we recommend that the 3 implementable strategies
we describe be introduced into real-world practice, particularly in a setting such as a quality
improvement network or a closed healthcare system where the impact of such strategies on
outcomes as well as cost can be measured and evaluated. We also present 4 emerging
exploratory considerations with growing evidence for future cost-efficiency. Although not
an exhaustive review on potential ways for improving cost-effectiveness of anti-TNF
therapy, this report focuses on the key evidence-based and practical ways to increase cost-
efficiency and decrease cost-burden associated with anti-TNF use. We acknowledge the
substantial variability in real-life use of anti-TNF agents without a clear consensus among
gastroenterologists (e.g., differences between pediatric and adult IBD states, precise
estimates of increased risk for lymphoma or infections when aggressively immune
suppressed)80.
Finally, since their real-life application is uncertain81, we did not elaborate on the
developing area of “biosimilars.” However, biosimilars are well-positioned to be a
disruptive force in European, Asian, and U.S. markets, competing directly with current
biologic agents82. Developmental stages of various biosimilars range from Phase 1 to
completed Phase 3 trials83, and early efficacy results are promising and may rival
mainstream anti-TNF agents84. The latest cost-savings forecast is $250 billion dollars over a
10 year span in the U.S. if 11 biosimilars are approved to compete with current brands of
biologic agents used across all diseases85. Most recently, Inflecta – a biosimilar version of
infliximab – has been approved for use in Europe by the European Medicines Agency.
Projected FDA-approval for use in the U.S. is possible as early as 201586.
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IBD inflammatory bowel disease
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